BioExx Files for Fourth Patent for Continuous Counter Flow bio-extraction facility
Bio-Extraction Inc. announced that it has filed a patent application, and now has a patent pending, for its design of a Continuous Counter flow ("CCF") bio-extraction facility and corresponding process. The technology represented by this innovation will play a key role in BioExx's pending commercial engagement of the massive global oilseeds (and bio-diesel) markets.
Traditionally, a methodology known as Continuous Counter Current ("CCC") has been used as the baseline design for very large scale extraction facilities that utilize conventional solvents, such as hexane. These legacy CCC facilities have therefore been designed for alignment with the properties of conventional higher-temperature operating solvents. Since the BioExx value proposition uniquely leverages the protein-retentive and compound-sensitive properties of its patented low-temperature extraction solvents, a novel process solution was required. This is the basis for the newly filed BioExx patent application, which BioExx calls Continuous Counter Flow ("CCF").
"With this patent application filing, we are extending the breadth of our proprietary technology from being solvent-based to now also being process-based. This extends our technology advantage directly into an economic advantage versus conventional extraction facilities, at any volume or scale, and allows us to immediately and aggressively enter major oilseed extraction markets, including bio-diesel." said Chris Carl, founder and President of BioExx. "While there are of course many applications that work well with the existing BioExx Continuous Batch process, our move to CCF will allow significant acceleration of our construction plans and will be applicable in our first full-scale commercial extraction facility."
The design and patent was completed through the hard work of the entire BioExx management team and through data accumulated at the BioExx R&D facilities in Charlottetown, PEI. The patent application has been filed in the United States. BioExx intends to use this filing as a basis for future patent applications in all of its targeted major global markets.
Other news from the department research and development
